Back

QuVa acquires critical medications from CAPS after 503B business exit

Verifying
  • QuVa acquired essential medications from CAPS after CAPS exited 503B sterile compounding.
  • QuVa operates more than 200,000 square feet of 503B manufacturing facilities.
  • QuVa plans phased product introductions later in 2026 and expansion over six months.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.